블로그
- [NMPA] China updates drug clinical trial guideline to enhance biotech innovation on Monday, the guideline updates the previous version that had been in effect since 2020. According to the administration, the revision .......
- 앤퀘르세틴 어떤 효능이 있을까 SN Biotech Co.,Ltd 체지방 감소효과 Enzymatically Modified Isoquercitrin(EMIQ)은 항비만·근기능 강화·이너뷰티를 포함하는 폭넓은 건강 Anti-obesity effects of heat-transformed green tea extract through the activation of adipose tissue thermogenesis
- 가장 큰 상승 잠재력을 가진 12개 바이오텍 미국 주식/RVMD/IONS/FOLD/DNLI/CRSP/RARE/CRNX/IMVT/MRUS/RNA/LEGN/VKTX 가장 큰 상승 잠재력을 가진 12개 바이오텍 주식 12 Biotech Stocks with the Biggest Upside Potential 원문 : https://www.insidermonkey.com /blog/12-biotech-stocks-with-the-biggest-upside-potential-1425221/?
- Electroceutical device uses light to improve blood flow in the brain, alleviating dementia symptoms Dementia is the most common degenerative brain disease associated with aging. The main cause of dementia.......
- Autophagy: Drugging the yin and yang of the cell Can biotech companies walk the fine line between boosting and inhibiting autophagy to treat disease without After the Nobel Prize was awarded for the discovery of autophagy genes in 2016, several biotech companies
- [공유]정부, 코로나19 치료제·백신 개발에 1936억 원 투입 Maryland biotech company. In May, the government awarded more than $1.2 billion to pharmace.......
- 제넥신, 코로나 백신 관련 뉴스, 내년 2분기 백신 시판 가능할 것 South Korea’s biotech firm Genexine will be able to market vaccine to prevent COVID-19 in the second half of next year, given the pace of simultaneous clinical trials in multiple countries, said the compa
- Coronavirus treatment: Vaccines/drugs in the pipeline for COVID-19 The pandemic has catalysed the development of novel coronavirus vaccines across the biotech industry, The first COVID-19 vaccine in China is expected to be ready for clinical trials by the end of April,
- LABU The fund normally creates long positions by investing at least 80% of its assets in the securities that comprise the index and/or financial instruments that provide leveraged and unleveraged exposure to the
- Clinical Comparison of the Treponema pallidum CAPTIA Syphilis-G Enzyme Immunoassay with the Fluoresc ) IgG assay were evaluated by the CAPTIA EIA. (RPR) testing of the same specimens.
1 페이지
다음 →